Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
122.87
+0.87 (0.71%)
At close: Aug 13, 2025, 4:00 PM
127.00
+4.13 (3.36%)
After-hours: Aug 13, 2025, 7:59 PM EDT
Insmed Revenue
Insmed had revenue of $107.42M in the quarter ending June 30, 2025, with 18.90% growth. This brings the company's revenue in the last twelve months to $398.11M, up 21.15% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$398.11M
Revenue Growth
+21.15%
P/S Ratio
55.80
Revenue / Employee
$313,222
Employees
1,271
Market Cap
25.97B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
INSM News
- 1 day ago - FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - Benzinga
- 1 day ago - US FDA approves Insmed's lung disease drug - Reuters
- 1 day ago - FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease - PRNewsWire
- 6 days ago - Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts - Seeking Alpha
- 6 days ago - Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 14 days ago - Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. - Barrons
- 20 days ago - Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 - PRNewsWire